文献速递衰弱、肌少症与跌倒多重用药

自报处方止痛药与助眠药使用与衰弱发病风险

Self-Reported Prescription Drug Use for Pain and for Sleep and Incident Frailty.
PubMed 文献 · J Am Geriatr Soc · 2019-10-24

基于美国健康与退休研究(HRS)的纵向队列,纳入基线非衰弱的社区居住65岁以上老年人(N=7201),评估处方止痛药和助眠药单用或共用与衰弱发病的关联。结果显示,两类药物使用均与衰弱风险升高相关,共用者风险最高(调整sHR=1.95),8年累积衰弱发生率随用药增加而升高。

要点

  • 处方止痛药和助眠药单用或共用均与衰弱发病风险升高独立相关。
  • 两药共用者衰弱风险最高(调整sHR=1.95),8年累积发生率60.6%。
  • 该关联为观察性结果,作者提示需进一步研究后方可据此建议减处方。

核心结论

  • 处方止痛药和助眠药使用与老年人衰弱发病率升高显著相关。
  • 作者指出,在依据这些发现提倡减处方之前,需进一步研究疼痛与睡眠适应症及药物类别特异性剂量和疗程对衰弱发病的影响。

研究设计与样本

  • 纵向队列研究,数据来自美国健康与退休研究(HRS)。
  • 纵向分析样本为基线非衰弱且至少有一次随访波次具有完整处方药使用和衰弱信息或死亡日期者(N=7201)。
  • 采用多变量药物使用分层风险模型,以死亡为竞争风险。

主要发现

  • 处方药使用比例:仅止痛药22.1%,仅助眠药6.8%,两者共用7.7%。
  • Burden衰弱模型患病率为41.0%,且随药物使用情况显著变化。
  • 基线非衰弱者中,仅止痛药、仅助眠药和两者共用的比例分别为14.9%、5.6%和2.2%。
  • 与未使用组相比,两药共用调整sHR=1.95(95%CI 1.6-2.4),仅止痛药调整sHR=1.58(95%CI 1.4-1.8),仅助眠药调整sHR=1.35(95%CI 1.1-1.6)。
  • 四组8年衰弱累积发生率分别为60.6%、50.9%、45.8%和34.1%。

临床怎么用

  • 对使用处方止痛药或助眠药的老年人,应关注衰弱风险,尤其两药共用者风险更高。
  • 作者不建议仅基于本研究结果常规减处方,需进一步研究明确适应症和药物类别特异性影响。

局限性

  • 作者指出需进一步研究疼痛与睡眠适应症及药物类别特异性剂量和疗程对衰弱发病的影响,提示当前证据尚不足以支持减处方建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to estimate incident frailty risks of prescription drugs for pain and for sleep in older US adults. DESIGN: Longitudinal cohort. SETTING: Health and Retirement Study. PARTICIPANTS: Community-living respondents aged 65 years and older, excluding individuals who received recent treatment for cancer (N = 14 208). Our longitudinal analysis sample included respondents who were not frail at baseline and had at least one follow-up wave with complete information on both prescription drug use and frailty, or date of death (N = 7201). MEASUREMENTS: Prescription drug use for pain and sleep, sociodemographics, other drug and substance use, and Burden frailty model components. Multivariable drug use stratified hazard models with death as a competing risk evaluated frailty risks associated with co-use and single use of prescription drugs for pain and for sleep. RESULTS: Proportions endorsing prescription drug use were 22.1% for pain only, 6.8% for sleep only, and 7.7% for both indications. Burden frailty model prevalence was 41.0% and varied significantly by drug use. Among non-frail individuals at baseline, proportions endorsing prescription drug use were 14.9%, 5.6%, and 2.2% for the three indications. Prescription drug use was associated with increased risk of frailty (co-use adjusted subhazard ratio [sHR] = 1.95; 95% confidence interval [CI] = 1.6-2.4; pain only adjusted sHR = 1.58; CI = 1.4-1.8; sleep-only adjusted sHR = 1.35; CI = 1.1-1.6; no use = reference group). Cumulative incidence of frailty over 8 years for the four groups was 60.6%, 50.9%, 45.8%, and 34.1%. Sensitivity analyses controlling for chronic diseases associated with persistent pain resulted in minor risk reductions. CONCLUSION: Prescription pain and sleep drug use is significantly associated with increased incidence of frailty. Research to estimate effects of pain and sleep indications and of drug class-specific dosage and duration on incident frailty is indicated before advocating deprescribing based on these findings. J Am Geriatr Soc 67:2474-2481, 2019.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Cil G, Park J, Bergen AW, et al. Self-Reported Prescription Drug Use for Pain and for Sleep and Incident Frailty. J Am Geriatr Soc. 2019. PMID: 31648384. doi:10.1111/jgs.16214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。